Spots Global Cancer Trial Database for Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

Official Title: A Phase II Study of Dasatinib (NSC #732517) in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer

Study ID: NCT00470054

Conditions

Extensive Stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

Recurrent Small Cell Lung Cancer

Interventions

dasatinib

Study Description

Brief Summary: This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description: PRIMARY OBJECTIVE I. Determine the efficacy of dasatinib in patients with relapsed small cell lung cancer. SECONDARY OBJECTIVE II. Determine the objective response rate (complete and partial response) in patients treated with this drug. III. Determine the overall survival of patients treated with this drug. IV. Determine the toxicity of this drug in these patients. OUTLINE: Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at least every 3 months for 1 year and then every 6 months for 3 years.